Search results
Showing 1 to 15 of 61 results for rheumatology
This quality standard covers assessing, diagnosing and managing rheumatoid arthritis in over 16s. It describes high-quality care in priority areas for improvement.
Rheumatology referral prioritisation: the right care in the right place at the right time
Organisation: Princess of Wales Hospital and British Society for Rheumatology Published date: January 2017
This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.
of Musculoskeletal Health , 2021. Diagnoses of people referred into rheumatology with suspected inflammatory arthritis // Early...
Spondyloarthritis in over 16s: diagnosis and management (NG65)
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
This guideline covers the diagnosis and management of gout. It includes recommendations on diagnosing gout, managing flares, long-term management of gout and referral to specialist services.
approach is called 'treat-to-target'. Data from the British Society of Rheumatology's National Early Inflammatory Arthritis (NEIA) Audit...
Developing an Annual Review Clinic for People with Rheumatoid Arthritis
Arthritis. The Annual Review is a 40 minute appointment carried out by a Rheumatology Nurse Specialist and is a holistic review of the...
database Organisation: British Society for Rheumatology and Manchester Royal Infirmary Published date:
Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis in adults.
Integrating service, audit and research data to improve patient care
Newcastle Upon Tyne NHS Foundation Trust & British Society for Rheumatology Published date: May 2017
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they haven’t worked well enough.
Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis (ES29)
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
Evidence-based recommendations on tocilizumab (RoActemra) for treating giant cell arteritis in adults.
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
In development [GID-TA10733] Expected publication date: TBC